You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恒瑞醫藥(600276.SH)收到國家藥監局核准簽發脯氨酸恒格列淨片的《藥品註冊證書》
格隆匯 06-30 17:14

格隆匯6月30日丨恒瑞醫藥(600276.SH)公吿,近日,江蘇恒瑞醫藥股份有限公司(以下簡稱“公司”)收到國家藥品監督管理局(以下簡稱“國家藥監局”)核准簽發脯氨酸恒格列淨片的《藥品註冊證書》,為該產品獲批上市的第2個適應症,該適應症的獲批使得脯氨酸恒格列淨成為目前中國唯一獲批與二肽基肽酶-IV(DPP-IV)抑制劑和二甲雙胍聯合治療方案的鈉-葡萄糖協同轉運蛋白2(SGLT2)抑制劑。

2021年12月,公司的脯氨酸恒格列淨片獲批上市,適用於改善成人2型糖尿病患者的血糖控制。單藥可配合飲食控制和運動,改善成人2型糖尿病患者的血糖控制;在單獨使用鹽酸二甲雙胍血糖控制不佳時,可與鹽酸二甲雙胍聯合使用,配合飲食和運動改善成人2型糖尿病患者的血糖控制。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account